ABEL [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2014-11-19 16:44 (4239 d 02:39 ago) – Posting: # 13884
Views: 16,343

Hi nobody & Angus,

❝ Other range of 90%-111% only for narrow therapeutic index drugs in Europe


AFAIK a generic of Concerta passed a centralised procedure a while ago. EMA accepted ABEL (i.e., widening of the acceptance range) not only for Cmax, but also for the (first only?) pAUC. The same is mentioned in the MR-Draft (line 810). Let’s wait for the final version.

I’m pretty sure that most (all?) other MR formulations in the EU were hybrid appli­ca­tions: BA-studies against IR MPH given twice (τ 4 hours) plus one (or more) therapeutic equivalence studies in children. BTW, approved MR for­mu­la­tions are not inter­change­able.1,2


    References:
  1. Haessler F, Tracik F, Dietrich H, Stammer H, Klatt J. A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Int J Clin Pharmacol Ther. 2008;46(9):466–76. PMID 18793577
  2. Schütz H, Fischer R, Großmann M, Mazur D, Leis HJ, Ammer R. Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteers. Int J Clin Pharmacol Ther. 2009;47(12):761–9. doi 10.5414/CPP47761
PS @nobody: Any particular reason why you linked the draft BE-GL?

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
350 visitors (0 registered, 350 guests [including 11 identified bots]).
Forum time: 20:23 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5